Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31626509 | 0.84 | SMN1; SMN2 (0.70) | PTGS2SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL16344554 | 0.84 | SMN1; SMN2 (0.59) | PTGS2SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL31626656 | 0.84 | SMN1; SMN2 (0.54) | PTGS2SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL4826104 | 0.83 | KMT2A (0.64) | PTGS2SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL16221641 | 0.83 | SMN1; SMN2 (0.56) | PTGS2SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL31626464 | 0.82 | ALDH1A1 (0.48) | PTGS2SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL31626571 | 0.82 | ALDH1A1 (0.49) | PTGS2SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL31626567 | 0.81 | ALDH1A1 (0.46) | PTGS2SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL2558779 | 0.80 | KMT2A (0.64) | PTGS2SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL17276671 | 0.79 | PTGS2 (0.59) | PTGS2SMN1; SMN2RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025125829-A1 | NORA INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2024-06-25 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-11566025-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-01-31 | — | — | US | disclosed |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECKA/S (DK) | 2022-12-20 | — | — | US | disclosed |
| CN-107982266-B | Carbamate compounds and methods of making and using the same | H.隆德贝克有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210188793-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2021-06-24 | — | — | US | disclosed |
| US-11021453-B2 | Carbamate compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| CN-105283451-B | Novel inhibitors of viral replication | 鲁汶天主教大学 | 2021-01-26 | — | — | CN | disclosed |
| US-20200270223-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2020-08-27 | — | — | US | disclosed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | disclosed |
| CN-101636388-B | 637 pyridopyrimidinediones as PDE4 inhibitors | ASTRAZENECA AB | 2013-09-18 | — | — | CN | disclosed |
| WO-2013103973-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-07-11 | — | — | WO | disclosed |
| CN-102532135-A | Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| CN-101636388-A | Compound 637: pyridopyrimidinediones as PDE4 inhibitors | ASTRAZENECA AB | 2010-01-27 | — | — | CN | disclosed |
| EP-2106396-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | AstraZeneca AB (SE) | 2009-10-07 | — | — | EP | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| WO-2008084223-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530189-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | PTGS2 3527/4885SMN1; SMN2 2374/4885RAB9A 458/4885 |
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | PTGS2 298/4885SMN1; SMN2 2231/4885RAB9A 1736/4885 |
| US-11021453-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | PTGS2 3477/4885SMN1; SMN2 2659/4885RAB9A 483/4885 |
| US-20210188793-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | PTGS2 3527/4885SMN1; SMN2 2374/4885RAB9A 458/4885 |
| US-11566025-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | PTGS2 2218/4885SMN1; SMN2 2456/4885RAB9A 776/4885 |
| US-20200270223-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, NCEH1 | PTGS2 3558/4885SMN1; SMN2 1553/4885RAB9A 742/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | PTGS2 3527/4885SMN1; SMN2 2374/4885RAB9A 458/4885 |
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | PTGS2 298/4885SMN1; SMN2 2231/4885RAB9A 1736/4885 |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | PTGS2 3527/4885SMN1; SMN2 2374/4885RAB9A 458/4885 |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | PDE4A, PDE4B, PDE5A | PTGS2 682/4885SMN1; SMN2 1660/4885RAB9A 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.